Pain in neuromyelitis optica and its effect on quality of life: A cross-sectional study

Neurology

Volumn 77, Issue 7, 2011, Pages 652-658

  Kanamori, Y ^a   Nakashima, I ^a   Takai, Y ^a   Nishiyama, S ^a   Kuroda, H ^a,b   Takahashi, T ^a,c   Kanaoka Suzuki, C ^a   Misu, T ^a,d   Fujihara, K ^a,d   Itoyama, Y ^a,e  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c Yonezawa National Hospital   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; HUMAN; JAPAN; LEG PAIN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; TRUNK; CROSS-SECTIONAL STUDY; HEALTH STATUS; HEALTH SURVEY; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 80055085027     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318229e694     Document Type: Article

References (40)

1. Kuroiwa Y. Neuromyelitis optica (Devic's disease, Devic's syndrome). In: Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers; 1985:397-408.
2. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-168. (Pubitemid 23223043)
3. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-387. (Pubitemid 26118744)
4. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114. (Pubitemid 29442132)
5. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460-2468. (Pubitemid 35303505)
6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489. (Pubitemid 43958540)
7. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461. (Pubitemid 34755161)
8. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364: 2106-2112. (Pubitemid 39626806)
9. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477. (Pubitemid 41186945)
10. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
11. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231. (Pubitemid 350294677)
12. Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009;20:508-512.
13. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-629.
14. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-216.
15. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575-577.
16. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010;12:244-255.
17. Solaro C, Lunardi GL, Mancardi GL. Pain and MS. Int MS J 2003;10:14-19.
18. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004;63:919-921. (Pubitemid 39297662)
19. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098-1103. (Pubitemid 29442130)
20. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006;12:629-638. (Pubitemid 46940637)
21. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch- Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003;60: 1089-1094. (Pubitemid 36975796)
22. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006;210:307-313. (Pubitemid 44883971)
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846. (Pubitemid 41746873)
24. Holen JC, Lydersen S, Klepstad P, Loge JH, Kaasa S. The Brief Pain Inventory: pain's interference with functions is different in cancer pain compared with noncancer chronic pain. Clin J Pain 2008;24:219-225. (Pubitemid 351640919)
25. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596. (Pubitemid 24065792)
26. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210. (Pubitemid 13012221)
27. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory: BPI-J. J Pain Symptom Manage 1998;16:364-373. (Pubitemid 29006199)
28. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-912. (Pubitemid 28527145)
29. Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:150-156. (Pubitemid 30245836)
30. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51:1037-1044. (Pubitemid 28527159)
31. Fukuhara S, Suzukamo Y. Manual of the SF-36v2 Japanese Version. Kyoto: Institute for Health Outcomes & Process Evaluation Research; 2004.
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
33. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study. J Neurol 2008;255: 163-170.
34. Finnerup NB, Gyldensted C, Nielsen E, Kristensen AD, Bach FW, Jensen TS. MRI in chronic spinal cord injury patients with and without central pain. Neurology 2003; 61:1569-1575. (Pubitemid 37505581)
35. Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet 2003;361:889-890. (Pubitemid 36332102)
36. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-1182. (Pubitemid 46608464)
37. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis: prevalence and clinical characteristics. Eur J Pain 2005;9:531-542. (Pubitemid 41222322)
38. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009;15:159-173.
39. Beiske AG, Naess H, Aarseth JH, et al. Health-related quality of life in secondary progressive multiple sclerosis. Mult Scler 2007;13:386-392. (Pubitemid 46706000)
40. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-1243. (Pubitemid 47355956)